In a recent interview with a Korean healthcare media outlet, Jason An, Founder and CEO of Medicus AI, shared the company’s vision for the future of digital pathology and AI-driven precision oncology.

The interview highlighted the journey behind Medicus AI, which builds on the foundation established in Korea through Urban Data Lab. Before launching its U.S. headquarters, the founding team worked closely with leading hospitals in Korea to support digital pathology adoption and develop AI-based solutions for pathology workflows and biomedical research.

During the interview, An introduced two major areas of focus. The first is an integrated digital pathology platform designed to support hospitals throughout their digital transformation journey. The second is an AI biomarker solution that helps researchers and clinicians better analyze cancer characteristics, biomarker expression, and treatment response through advanced pathology data analysis.

An also explained the strategic importance of Medicus AI’s U.S. headquarters. By establishing its base in the United States, the company aims to expand collaboration with global healthcare, biotechnology, and research partners while accelerating the development and validation of next-generation AI solutions in pathology.

Looking ahead, Medicus AI plans to continue advancing technologies that connect digital pathology, artificial intelligence, and multi-omics data. The company’s long-term vision is to contribute to a future where more precise analysis supports better research, drug development, and patient care in oncology and beyond.

Source: Based on a Korean-language media interview with Jason An, Founder and CEO of Medicus AI, originally published by Medical Times Korea. [Read the original Korean article]

Note: This article is a summarized and adapted version prepared for the Medicus AI website.